Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships

Qiagen N.V. (NYSE:QGEN) has announced two strategic partnerships designed to revolutionize minimal residual disease (MRD) testing in oncology, further cementing its leadership in precision diagnostics. The company is teaming up with Tracer Biotechnologies to develop blood-based MRD assays for solid tumors using the QIAcuity digital PCR platform.

This collaboration aims to deliver rapid, cost-effective, and highly sensitive tests that can be easily implemented in decentralized clinical laboratories, providing oncologists with powerful tools for early cancer recurrence detection.

Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships

An oncologist examining an MRI scan showing tumors being targeted by Alpha Particles.

Simultaneously, Qiagen N.V. (NYSE:QGEN) is partnering with Foresight Diagnostics to create a kit-based version of the CLARITY NGS assay, a cutting-edge circulating tumor DNA test for lymphoma. This move will transition the assay from a central lab service to a widely accessible in-lab kit, supporting broader clinical and pharmaceutical applications.

These alliances reflect Qiagen N.V. (NYSE:QGEN)’s commitment to advancing personalized cancer care and supporting pharmaceutical partners in developing companion diagnostics.

With MRD testing becoming a key tool for monitoring treatment response and accelerating drug development, QGEN’s expanded portfolio is set to play a pivotal role in the future of oncology diagnostics.

Qiagen N.V. (NYSE:QGEN), based in the Netherlands, is a global leader in Sample to Insight solutions. The company provides technologies to extract and analyze DNA, RNA, and proteins from various samples. Its offerings include sample preparation, assay development, bioinformatics software, and automation to deliver efficient, integrated workflows. Serving over 500,000 customers worldwide across life sciences and molecular diagnostics, QIAGEN supports research, clinical, and industrial applications. As of March 2025, QIAGEN employs about 5,700 people across 35+ locations globally.

While we acknowledge the potential of QGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QGEN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.